In short
A new clinical trial is investigating the use of Falbikitug (AZD0171) in combination with other treatments for patients with early-stage, resectable non-small cell lung cancer (NSCLC). This Phase II study aims to evaluate the effectiveness and safety of using Falbikitug as part of neoadjuvant (before surgery) and adjuvant (after surgery) treatment approaches. The trial focuses on patients with Stage II to IIIB NSCLC and seeks to improve outcomes for those diagnosed with this challenging disease.
At a glance
- Study Type
- Phase II, open-label, multicentre, randomised
- Target Population
- Patients with resectable, early-stage (II to IIIB) non-small cell lung cancer
- Main Objectives
- Assess antitumor activity of neoadjuvant treatment and safety/tolerability of neoadjuvant/adjuvant treatment
- Primary Endpoints
- Pathological Complete Response (pCR), Safety and tolerability
- Secondary Endpoints
- Event-free survival, Disease-free survival, Feasibility of surgery, Objective response rate, Overall survival
- Key Inclusion Criteria
- Newly diagnosed NSCLC (Stage IIA to IIIB), Good performance status, Adequate organ function
- Key Exclusion Criteria
- Certain genetic mutations, Autoimmune disorders, Prior immunotherapy exposure
- Treatment Approach
- Neoadjuvant therapy followed by surgery and adjuvant therapy
What is FALBIKITUG?
FALBIKITUG, also known as AZD0171, is a new medication being studied for the treatment of early-stage non-small cell lung cancer (NSCLC). It is a type of drug called a humanized monoclonal antibody, which is a laboratory-made protein that mimics the immune system's ability to fight harmful cells. Specifically, FALBIKITUG targets a protein called LIF (Leukemia Inhibitory Factor), which is part of a family of proteins known as interleukin 6 family cytokines.
Medical Conditions Treated
FALBIKITUG is being investigated for the treatment of resectable, early-stage (II to IIIB) non-small cell lung cancer. This means it's intended for patients who have lung cancer that: Is classified as non-small cell lung cancer (NSCLC), which is the most common type of lung cancer Is in an early stage (stage II to IIIB), meaning the cancer has not spread widely throughout the body Is considered resectable, which means it can potentially be removed through surgery
How FALBIKITUG Works
While the exact mechanism of action is not fully described in the provided information, we can infer some details based on what we know about FALBIKITUG: As a monoclonal antibody, it's designed to target specific proteins in the body. It targets the LIF protein, which is involved in various cellular processes and may play a role in cancer growth. By targeting LIF, FALBIKITUG may help to slow down or stop the growth of cancer cells, potentially making tumors easier to remove surgically or more responsive to other treatments.
Clinical Trial Details
FALBIKITUG is currently being studied in a Phase II clinical trial called NeoCOAST-2. Here are some key details about the trial: It's an open-label, multicentre, randomized study, which means participants and researchers know which treatment is being given, it's conducted at multiple hospitals or clinics, and participants are randomly assigned to different treatment groups. The study is looking at both neoadjuvant treatment (given before surgery) and adjuvant treatment (given after surgery). The main goals of the study are to assess how well the treatment works in shrinking tumors before surgery and to evaluate its safety and tolerability. Secondary goals include looking at how the treatment affects survival rates, how feasible it is for patients to proceed to surgery after treatment, and how the drug behaves in the body.
Eligibility Criteria
To participate in the clinical trial for FALBIKITUG, patients must meet certain criteria. Some key eligibility factors include: Having newly diagnosed NSCLC that is resectable and in stage IIA to IIIB Being in good overall health (WHO or ECOG performance status of 0 or 1) Having adequate organ and bone marrow function Being able to provide tumor samples for testing There are also several factors that would exclude a patient from participating, such as having certain genetic mutations, severe heart problems, or autoimmune disorders.
Potential Benefits
While it's important to note that FALBIKITUG is still in the research phase and its benefits are not yet fully known, the clinical trial aims to assess several potential benefits: Shrinking tumors before surgery (measured as pathological complete response or pCR) Improving the success rate of surgery Extending the time patients live without their cancer returning or getting worse (event-free survival and disease-free survival) Increasing overall survival rates
Safety and Side Effects
As FALBIKITUG is still in clinical trials, its full safety profile is not yet established. The NeoCOAST-2 study is specifically designed to evaluate the safety and tolerability of the drug. This will involve monitoring: Adverse events (side effects) Vital signs Clinical laboratory parameters Patients considering participating in the clinical trial should discuss potential risks and side effects with their healthcare provider and the research team.